Scene-setting presentation by David Elvira, Head of Global Corporate Public Policy, Sanofi at the 2022 GGSD Forum, Session 3 "International co-operation to accelerate green technology innovation and transfer"

1. International cooperation to
accelerate green technology
innovation and transfer
OECD Green Growth and Sustainable Development Forum 2022
David Elvira, Head of Global Corporate Public Policy

2. 2
International cooperation brought
unprecedented science-based solutions
to the pandemic
Surveillance, rapid data sharing, and access to pathogens across
the scientific community was crucial in developing tests, medicines and
vaccines
Collaborative consultations with industry and regulators helped
secure safety and efficacy of vaccines and medicines at a record pace
Partnerships helped accelerate R&D and manufacturing, facilitated
technology and knowledge transfer
Established governance structures for advanced market
commitments and procurement allowed for supplemental investments
in production capacity
Pre-
clinical,
10
Phase I
Clinical
Phase II
Clinical
Phase III
Regulato
ry
Approval
Standard Accelerated
For more details: https://coronavirus.jhu.edu/vaccines/timeline
Vaccine Development
Timelines (est.)
~ 10-12 years
~1-2 years
Efforts at clinical
trials’ level, fast
track regulatory
process, joint
assessment of
regional
regulatory
authorities and
parallel security-
safety revisions…

3. This multi-crisis era puts science and
innovation at the forefront
• Continuous knowledge and data sharing will be critical
(e.g., in pathogen sharing and biodiversity protection)
• Sustained investments in research and development will
help drive innovation across sectors to bring solutions
• Global regulatory and legal frameworks are key in
incentivizing innovation
• Partnerships and coalitions are essential in addressing
global public good issues

4. 4
Accelerating green growth through the
delivery of net-zero health systems
Challenges
Data gaps in and emission
baselining of the biopharma
value chain
Lack of regulatory
standards that account for
low-carbon treatments or
care delivery models
Limited solutions that are
economic and easily
scalable
1
2
3
Seven levers to reduce emmissions in care pathways
Decarbonizing
facilities
Improving prevention and care
Decarbonizing
facilities and
fleets
Preventing
disease
onset
Diagnosing
early
Optimizing
disease
management
Delivering care differently
Improving
the efficiency
of
interventions
Delivering
care
remotely or
closer to
home when
appropriate
Using lower
émission
treatments
Source: Health Care Without Harm, WHO, academic literature, BCG analysis

5. Thank you